Cantor Fitzgerald Comments on CRBU FY2025 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Caribou Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski forecasts that the company will earn ($1.31) per share for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. The firm had revenue of $2.02 million for the quarter, compared to the consensus estimate of $3.37 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%.

Several other analysts also recently commented on CRBU. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a research report on Friday, November 15th. Bank of America reduced their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Citigroup lowered their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 26th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $10.33.

Caribou Biosciences Stock Performance

NASDAQ CRBU opened at $1.52 on Thursday. Caribou Biosciences has a 1 year low of $1.50 and a 1 year high of $8.33. The company has a fifty day moving average of $1.85 and a two-hundred day moving average of $2.00.

Institutional Trading of Caribou Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Erste Asset Management GmbH acquired a new stake in Caribou Biosciences in the 3rd quarter valued at $28,000. AQR Capital Management LLC purchased a new position in Caribou Biosciences in the 2nd quarter worth approximately $30,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Caribou Biosciences by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock worth $34,000 after purchasing an additional 6,768 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Caribou Biosciences during the 3rd quarter worth $43,000. Finally, Point72 DIFC Ltd lifted its stake in shares of Caribou Biosciences by 389.4% in the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock worth $49,000 after acquiring an additional 23,995 shares in the last quarter. Institutional investors and hedge funds own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.